Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies.

Aim: To evaluate tolerability of a new extended-release acetylsalicylic acid (ER-ASA).

Materials & Methods: Daily ER-ASA (162.5-1300 mg) for up to 6 weeks was evaluated (four studies; n = 565).

Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.

Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing.